Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection

A. J. Matas, P. F. Gores, S. L. Kelley, M. Bielefield-Skrokov, M. Kinaszczuk, Rainer W G Gruessner, J. S. Najarian

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

15-deoxyspergualin (DSG) is a novel immunosuppressant which has been shown to be effective in preventing and treating rejection in animal allo- and xenotransplant models. Preliminary clinical studies suggest that DSG is an effective antirejection agent. In our study, 4 patients with biopsy-proven rejection episodes that were resistant to steroid and antibody therapy were then treated with DSG. All 4 rejection episodes responded to DSG therapy and all 4 kidneys continue to function (follow-up 7-15 months). However, 2 patients had additional rejection episodes after DSG therapy. Side effects during DSG treatment were minimal; 1 patient, who had also had multiple courses of antibody, developed a lymphoproliferative tumor 2 months after DSG administration. We conclude that DSG is effective in treating refractory renal transplant rejection episodes. Additional studies are necessary to determine the ideal place for DSG in treating renal transplants recipients with rejection.

Original languageEnglish (US)
Pages (from-to)116-119
Number of pages4
JournalClinical Transplantation
Volume8
Issue number2 I
StatePublished - 1994
Externally publishedYes

Fingerprint

Graft Rejection
Kidney
gusperimus
Antibodies
Therapeutics
Immunosuppressive Agents
Steroids
Biopsy

Keywords

  • 15-deoxyspergualin
  • Renal transplant rejection

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

Matas, A. J., Gores, P. F., Kelley, S. L., Bielefield-Skrokov, M., Kinaszczuk, M., Gruessner, R. W. G., & Najarian, J. S. (1994). Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clinical Transplantation, 8(2 I), 116-119.

Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. / Matas, A. J.; Gores, P. F.; Kelley, S. L.; Bielefield-Skrokov, M.; Kinaszczuk, M.; Gruessner, Rainer W G; Najarian, J. S.

In: Clinical Transplantation, Vol. 8, No. 2 I, 1994, p. 116-119.

Research output: Contribution to journalArticle

Matas, AJ, Gores, PF, Kelley, SL, Bielefield-Skrokov, M, Kinaszczuk, M, Gruessner, RWG & Najarian, JS 1994, 'Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection', Clinical Transplantation, vol. 8, no. 2 I, pp. 116-119.
Matas AJ, Gores PF, Kelley SL, Bielefield-Skrokov M, Kinaszczuk M, Gruessner RWG et al. Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. Clinical Transplantation. 1994;8(2 I):116-119.
Matas, A. J. ; Gores, P. F. ; Kelley, S. L. ; Bielefield-Skrokov, M. ; Kinaszczuk, M. ; Gruessner, Rainer W G ; Najarian, J. S. / Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection. In: Clinical Transplantation. 1994 ; Vol. 8, No. 2 I. pp. 116-119.
@article{6e126ace607c401e95e1e0f8cba561a5,
title = "Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection",
abstract = "15-deoxyspergualin (DSG) is a novel immunosuppressant which has been shown to be effective in preventing and treating rejection in animal allo- and xenotransplant models. Preliminary clinical studies suggest that DSG is an effective antirejection agent. In our study, 4 patients with biopsy-proven rejection episodes that were resistant to steroid and antibody therapy were then treated with DSG. All 4 rejection episodes responded to DSG therapy and all 4 kidneys continue to function (follow-up 7-15 months). However, 2 patients had additional rejection episodes after DSG therapy. Side effects during DSG treatment were minimal; 1 patient, who had also had multiple courses of antibody, developed a lymphoproliferative tumor 2 months after DSG administration. We conclude that DSG is effective in treating refractory renal transplant rejection episodes. Additional studies are necessary to determine the ideal place for DSG in treating renal transplants recipients with rejection.",
keywords = "15-deoxyspergualin, Renal transplant rejection",
author = "Matas, {A. J.} and Gores, {P. F.} and Kelley, {S. L.} and M. Bielefield-Skrokov and M. Kinaszczuk and Gruessner, {Rainer W G} and Najarian, {J. S.}",
year = "1994",
language = "English (US)",
volume = "8",
pages = "116--119",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2 I",

}

TY - JOUR

T1 - Pilot evaluation of 15-deoxyspergualin for refractory acute renal transplant rejection

AU - Matas, A. J.

AU - Gores, P. F.

AU - Kelley, S. L.

AU - Bielefield-Skrokov, M.

AU - Kinaszczuk, M.

AU - Gruessner, Rainer W G

AU - Najarian, J. S.

PY - 1994

Y1 - 1994

N2 - 15-deoxyspergualin (DSG) is a novel immunosuppressant which has been shown to be effective in preventing and treating rejection in animal allo- and xenotransplant models. Preliminary clinical studies suggest that DSG is an effective antirejection agent. In our study, 4 patients with biopsy-proven rejection episodes that were resistant to steroid and antibody therapy were then treated with DSG. All 4 rejection episodes responded to DSG therapy and all 4 kidneys continue to function (follow-up 7-15 months). However, 2 patients had additional rejection episodes after DSG therapy. Side effects during DSG treatment were minimal; 1 patient, who had also had multiple courses of antibody, developed a lymphoproliferative tumor 2 months after DSG administration. We conclude that DSG is effective in treating refractory renal transplant rejection episodes. Additional studies are necessary to determine the ideal place for DSG in treating renal transplants recipients with rejection.

AB - 15-deoxyspergualin (DSG) is a novel immunosuppressant which has been shown to be effective in preventing and treating rejection in animal allo- and xenotransplant models. Preliminary clinical studies suggest that DSG is an effective antirejection agent. In our study, 4 patients with biopsy-proven rejection episodes that were resistant to steroid and antibody therapy were then treated with DSG. All 4 rejection episodes responded to DSG therapy and all 4 kidneys continue to function (follow-up 7-15 months). However, 2 patients had additional rejection episodes after DSG therapy. Side effects during DSG treatment were minimal; 1 patient, who had also had multiple courses of antibody, developed a lymphoproliferative tumor 2 months after DSG administration. We conclude that DSG is effective in treating refractory renal transplant rejection episodes. Additional studies are necessary to determine the ideal place for DSG in treating renal transplants recipients with rejection.

KW - 15-deoxyspergualin

KW - Renal transplant rejection

UR - http://www.scopus.com/inward/record.url?scp=0028269460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028269460&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 116

EP - 119

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2 I

ER -